Moricizine Hydrochloride

盐酸莫雷西嗪

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMoricizine Hydrochloride
Drug Alias Name噻吗嗪Moracizine hydrochloride吗拉西嗪盐酸莫里西嗪盐酸乙吗噻嗪 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type V alpha subunit blockers
TargetsSodium channel protein type V alpha subunit
Therapy Area/IndicationsArrhythmias, CardiacHeart DiseasesCardiovascular Diseases
Global Approved IndicationsArrhythmias, Cardiac
Approved Indications in ChinaArrhythmias, Cardiac
Original Approved Country/TerritoryUnited States
Original Approved Date1990/06/19
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShire
China Registration ClassN/A

Develop Information

Active CompaniesShenyang China Medical University Pharmaceutical Co Ltd
Inactive CompaniesNational Heart, Lung, And Blood Institute (Nhlbi)Shire Development Llc
Active IndicationsArrhythmias, Cardiac
Inactive IndicationsHeart DiseasesCardiovascular Diseases

Other Information

ATC CodeC01BG01
Related LinksWikipediaDrugBankKEGG